Osteosarcoma is typically a disease of the young, but may affect any age. Little is known about the disease in older patients beyond retirement age. We aim to describe the characteristics, treatment, and outcomes of older adult patients registered with our cooperative group.
Materials and Methods
The database of the Cooperative Osteosarcoma Study Group (COSS) was searched for osteosarcoma patients diagnosed from 1980 to 2020 who were aged 65 years or older at diagnosis. Affected individuals were analyzed for presenting factors, treatments employed, and outcomes.
Fifty-five eligible patients were detected (median age 68 [range: 65–84] years; male:female = 25:30). Among these patients, 15/55 (27%) tumors were secondary malignancies, 41/55 (75%) were high-grade central, 4/55 (7%) surface, and 10/55 (18%) extraosseous malignancies, and all but three high-grade. Primary metastases were present in 15/55 (27%) patients. Surgery was reported for 46/55 (84%) patients, radiotherapy for 6/54 (11%, 1 unknown), chemotherapy for 42/50 (84%, 5 unknown). A complete surgical remission was achieved in 31/55 (56%). There were two toxic deaths. With a median follow-up of 1.7 (range: 0.1–18.0) years for all 55 patients and 2.2 (0.1–12.4) years for 24 survivors, event-free and overall survival at 2/5 years were 39.6% (standard error: 6.8%) / 24.5% (6.5%) and 62.0% (7.1%) / 32.7% (7.5%), respectively. Tumor site, metastatic status, surgery, and a complete surgical remission were prognostic for event-free and/or overall survival.
Osteosarcomas can occur in older individuals. It is more often secondary, axially located, or extraosseous than in younger patients. However, the same treatment principles seem to apply, and selected patients may be cured. Multi-center cooperation is encouraged, thereby gathering expertise for such a rare disease presentation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Geriatric Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Osteosarcoma - approach to therapy. C. A. S. Arndt (ed.), Sarcomas of Bone and Soft Tissues in Children and Adolescents, Pediatric Oncology.2021https://doi.org/10.1007/978-3-030-51160-9_8
- Characteristics and prognostic factors of patients with osteosarcoma older than 60 years from the SEER database.Cancer Control. 2019; 26 (1073274819888893)https://doi.org/10.1177/1073274819888893
- EURO-B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma.Tumori. 2018 Jan-Feb; 104: 30-36https://doi.org/10.5301/tj.5000696
- Osteosarcoma in patients older than 65 years.J Clin Oncol. 2008 Nov 20; 26: 5368-5373https://doi.org/10.1200/JCO.2007.14.9104
- Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese musculoskeletal oncology group.J Surg Oncol. 2009 Jul 1; 100: 48-54https://doi.org/10.1002/jso.21287
- The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.BMC Cancer. 2018 May 31; 18: 614https://doi.org/10.1186/s12885-018-4487-2
- Osteosarcoma over the age of forty.Eur J Cancer. 2003 Jan; 39: 157-163https://doi.org/10.1016/s0959-8049(02)00478-1
- Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program.Cancer. 2009 Apr 1; 115: 1531-1543https://doi.org/10.1002/cncr.24121
- Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases.Ann Surg Oncol. 2014 Jan; 21: 263-268https://doi.org/10.1245/s10434-013-3210-4
- Osteosarcoma: the COSS experience.Cancer Treat Res. 2009; 152: 289-308https://doi.org/10.1007/978-1-4419-0284-9_15
- A system for the surgical staging of musculoskeletal sarcoma.Clin Orthop Relat Res. 1980 Nov-Dec; 153: 106-120
- Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren.Pathologie. 1983; 4: 135-141
- Nonparametric estimation from incomplete observations.J Am Stat Assoc. 1958; 53: 457-481
- Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep. 1966; 50: 163-170
- The etiology of osteosarcoma.Cancer Treat Res. 2009; 152: 15-32https://doi.org/10.1007/978-1-4419-0284-9_2
- The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.Ann Oncol. 2011 May; 22: 1228-1235https://doi.org/10.1093/annonc/mdq589
- Extraskeletal osteosarcoma: a European musculoskeletal oncology society study on 266 patients.Eur J Cancer. 2017 Mar; 74: 9-16https://doi.org/10.1016/j.ejca.2016.12.016
- Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database.Cancer Epidemiol. 2015 Aug; 39: 593-599https://doi.org/10.1016/j.canep.2015.05.001
Published online: February 24, 2023
Accepted: January 30, 2023
Received in revised form: November 16, 2022
Received: September 27, 2022
© 2023 Elsevier Ltd. All rights reserved.